ALSO NOTED: Nuvelo gains equity financing; First federal Vioxx trial scheduled; Anadys prices stock offering; and much more...

> Nuvelo has lined up an equity financing facility for up to $75 million. Report

> The first federal case on Vioxx is scheduled to start November 28 and focus on the death of a 53-year-old Florida man. Story

> San Diego-based Anadys has priced a stock offering of 5 million shares at $12.40 each. Release

> DOV Pharmaceutical of Hackensack, New Jersey, has begun a Phase III trial of bicifadine in the treatment of post-operative pain following vaginal hysterectomy. Release

> Sankyo has granted Schering-Plough marketing rights to the hypertension drug olmesartan in several Latin American countries. Release

And Finally... The World Health Organization is pressing China to find out why a bacterial disease in pigs has led to 38 deaths. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.